Clinical trials: Local Disease
Diabetes
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
The study aims to investigate the clinical characteristics, treatment, and economic burden of disease of Chinese diabetic/non-diabetic patients with/without established cardiovascular disease (CVD), chronic kidney disease (CKD)…
- Trial name
- NCT04903496
- Where
- China
- Volunteers
- 1,233,162 people
- Sponsor
- Boehringer Ingelheim
Gastroesophageal Reflux Disease
Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US
The purpose of this research study is to compare the safety and effectiveness (how well the medicine works) of esomeprazole (study drug) to placebo (a capsule that does not contain any medication) taken daily in relieving…
- Trial name
- NCT00660660
- Testing
- Esomeprazole
- Where
- 45 sites in United States
- Volunteers
- 276 people
- Sponsor
- AstraZeneca
Crohns Disease
Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients
The study is being conducted to evaluate the pharmacokinetic parameters (Cmax, Tmax and AUC) of the new delayed release, lowered dose, 40 mg 6MP test formulation as compared to standard 6MP (100 mg Purinethol) in 12 patients with…
- Trial name
- NCT00774982
- Testing
- Delayed Release 6 mercaptopurine, 6 Mercaptopurine
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Teva GTC
Liver Fibrosis, HEPATITIS B CHRONIC
A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients
The purpose of this study is to determine whether an investigational drug DCB-BO1202 is effective and safe in the treatment of liver fibrosis in HBV patients having experienced intermediate stage hepatocellular carcinoma (HCC)
- Conditions
- Liver Fibrosis, HEPATITIS B CHRONIC, Hepatocellular Carcinoma
- Trial name
- NCT02289300
- Testing
- DCB-BO1202
- Where
- Taiwan
- Sponsor
- A2 Healthcare Taiwan Corporation
Haemophilus Influenzae Type b (Hib) Infection
Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants
This study will evaluate the safety and immunogenicity of booster dose of two commercially available vaccines used to prevent Haemophilus influenzae type b infections in children 365-569 days of age
- Trial name
- NCT01226953
- Testing
- Haemophilus influenzae type b (Hib) vaccine
- Where
- China
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Healthy, Actinic Keratosis
PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects
The purpose of this phase 1 trial is to investigate the local tolerability on the finger following exposure to PEP005 Gel 0.015% or 0.05% and hand washing once daily, for 2 or 3 consecutive days.
- Trial name
- NCT01302925
- Testing
- PEP005 Gel
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peplin
Otitis Media With Effusion, Acute Otitis Media
Evaluation of Outcomes Following In-office Tympanostomy Using the Tula® System: a Prospective, Multi-center Registry
This prospective, single-arm, multicenter registry is being conducted to collect real world post-market data from patients aged from 6 months to 17 years of age who are undergoing an in-office ear tube placement procedure…
- Conditions
- Otitis Media With Effusion, Acute Otitis Media, Otitis Media
- Trial name
- NCT05915078
- Testing
- Iontophoresis and tube placement
- Where
- 6 sites in United States
- Volunteers
- 200 people
- Sponsor
- Smith & Nephew, Inc.
Osteoarthritis, Knee
Efficacy and Safety of G001 in Patients With Osteoarthritis (OA) of the Knee
Phase 2 multicenter, double-blind, randomized, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, and local tolerability of G001 topical gel compared to matching Vehicle topical gel in patients with…
- Trial name
- NCT05007808
- Testing
- G001 Topical Gel, Vehicle
- Where
- 10 sites in Canada
- Volunteers
- 210 people
- Sponsor
- BUZZZ Pharmaceuticals Limited
Glioblastoma Multiforme
Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy
The current study will investigate whether the addition of Neuradiab to surgery, radiation and adjuvant chemotherapy (temozolomide) will improve the survival of patients with glioblastoma and whether the drug regimen is safe.
- Trial name
- Glass-Art (NCT00615186)
- Testing
- Neuradiab + Radiotherapy + Temozolomide, Radiation Therapy + Temozolomide
- Volunteers
- 9 people
- Sponsor
- Bradmer Pharmaceuticals Inc.
Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy
CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1
This is a randomized, double-blind, placebo-controlled, 24-week study to evaluate the efficacy and safety of AXS-02 in patients with CRPS-I.
- Trial name
- CREATE-1 (NCT02504008)
- Testing
- AXS-02 (oral zoledronate)
- Where
- 44 sites in United States, Australia and 2 more
- Volunteers
- 190 people
- Sponsor
- Axsome Therapeutics, Inc.
Hemophilia A
Kogenate FS Regulatory Post-Marketing Surveillance
To obtain data on safety, efficacy, and tolerability of KOGENATE FS under real-life conditions in its registered indications. The observation period for each patient is up to 6 months.
- Trial name
- KG0910KR (NCT01386268)
- Testing
- Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Bayer
Spinal Fusion, Pain Management
PK Study of EXPAREL in Subjects Undergoing Open Spinal Fusion or Reconstructive Surgery
The primary objective of this study is to characterize the pharmacokinetic (PK) profile of EXPAREL when administered via local wound infiltration to subjects undergoing open spinal fusion or reconstructive surgery.
- Trial name
- NCT02985762
- Testing
- EXPAREL
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Bladder Neoplasms
Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer
The purpose of this study is to determine the efficacy and safety of intravesical Mycobacterial Cell Wall-DNA Complex (MCC) in patients with non-muscle invasive transitional cell carcinoma (papillary tumors and/or carcinoma in…
- Trial name
- NCT00406068
- Testing
- Mycobacterial cell wall-DNA complex
- Where
- 31 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- Bioniche Life Sciences Inc.
Asthma
A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A
GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor that attenuates the production of leukotrienes through the blockage of the first step in the leukotriene pathway, 5-lipoxygenase (5-LO) activation.
- Trial name
- NCT01318980
- Testing
- GSK2190915 100mg milled tablet, [14C] radiolabelled GSK2190915 solution, GSK2190915 100mg milled tablet administered to the proximal small bowel.
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Common Cold
Warming Sensation and Tolerability Study of Acetylcysteine 2% Oral Solution for Productive Cough
This is a 1-treatment arm, open label design. This 1-day study includes a screening on day of attendance at clinic, followed by a washout period of 30 minutes to 8 hours (if participants are eligible for dosing the same day).
- Trial name
- NCT02822287
- Testing
- Acetylcystine
- Where
- Germany
- Volunteers
- 58 people
- Sponsor
- GlaxoSmithKline
Local Metastatic Melanoma
DNA Repair Inhibitor & Irradiation on Melanoma
Phase I trial will be conducted in patients suffering local metastatic melanoma with relapsed cutaneous/subcutaneous tumors including melanoma-in-transit.
- Trial name
- DRIIM (NCT01469455)
- Testing
- DT01
- Where
- 12 sites in France
- Volunteers
- 27 people
- Sponsor
- DNA Therapeutics
Pain
S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults
Lasers are used for non-ablative resurfacing of facial rhytides, atrophic scars, and a variety of epidermal and dermal lesions. Pain associated with the non-ablative laser treatment has been described as moderate to severe.
- Trial name
- NCT00110747
- Testing
- S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- ZARS Pharma Inc.
Glioblastoma Multiforme, Brain Neoplasms
A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma
OncoGel™ is a new, experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel™) over a long period of time.
- Trial name
- NCT00479765
- Testing
- OncoGel (ReGel/Paclitaxel)
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Boston Scientific Corporation
Gingival Inflammation
Investigation of the Interplay Between Local Oral Inflammation, Microbiota and Systemic Immune Responses.
This is a clinical research study designed to measure changes in inflammation and the oral microbiome during a phase of good oral hygiene and the absence of oral hygiene.
- Trial name
- ILIMSIR (NCT06966492)
- Testing
- Stannous Fluoride Toothpaste (SnF)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Alzheimer's Disease
A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension
This is Phase 3 study, multi-centre, double-blind, placebo controlled, parallel group to evaluate the effects of AC-SD-03 on the efficacy and safety among participants with mild to moderate Alzheimer's Disease.
- Trial name
- NCT04187547
- Testing
- Tricaprilin
- Sponsor
- Cerecin